Open AccessEfficacy of a Specific Polyclonal Equine F(ab’) 2 Against Avian Influenza (H5N1) in Ferrets: Synergy with Oseltamivir
Author(s) -
Cécile H. Herbreteau,
Mélanie Denizot,
Suzanne Lowther,
Sarah Riddell,
Leah Frazer,
Jessica Haining,
Rachel Arkinstall,
Jean Payne,
Jennifer Harper,
Dayna A. Johnson,
Anaïs Pasquier,
Deborah Middleton,
Jean-François Saluzzo
Publication year - 2016
Publication title -
immunotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.127
H-Index - 48
eISSN - 1750-7448
pISSN - 1750-743X
DOI - 10.2217/imt-2016-0062
Subject(s) - oseltamivir , influenza a virus subtype h5n1 , polyclonal antibodies , virology , medicine , immunology , antiviral drug , viral load , antibody , biology , virus , covid-19 , infectious disease (medical specialty) , disease
Aim: Current therapies against avian influenza (H5N1) provide limited clinical benefit. FBF-001 is a highly purified equine polyclonal immunoglobulin fragment against H5N1. Methods: Using a ferret model of severe acute H5N1 infection, we assessed FBF-001 when administered on the same day or 1 day after viral challenge, in comparison with oseltamivir therapy. Results: Untreated animals died 2–3 days after challenge. FBF-001 prevented most severe illness and reduced nasal viral load, with best efficacy when administered on the day of viral challenge. Oseltamivir and FBF-001 had synergistic impact on survival. Conclusion: FBF-001 prevented severe consequences of lethal H5N1 challenge in ferrets by controlling viral replication, an effect synergistic to oseltamivir. FBF-001 has recently been granted EMA orphan drug status.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom